Objective. Infiltration of neutrophils into the joints plays an important role in bone erosion and articular destruction in rheumatoid arthritis (RA). Neutrophil trafficking during inflammation is a process that involves activation of chemotactic receptors. Recent findings suggest that changes in chemotactic receptor patterns could occur in neutrophils under certain inflammatory conditions. The aim of this study was to evaluate the gain of responsiveness of neutrophils to CCL2 in RA patients and to assess the role of CCL2 in driving neutrophil infiltration into the joints.
Methods. Neutrophils were purified from the peripheral blood of patients with RA or from mice with antigen-induced arthritis (AIA). Expression of CCR2 was evaluated using polymerase chain reaction, flow cytometry, and immunofluorescence analyses. In vitro chemotaxis to CCL2 was assayed to evaluate the functional significance of de novo CCR2 expression. The murine AIA model was used to evaluate the in vivo role of CCR2 in neutrophil infiltration into the joints.
Results. High CCR2 expression and responsiveness to CCL2 were observed in neutrophils from the blood of patients with early RA and in neutrophils from the blood and bone marrow of mice with AIA. Genetic deficiency or pharmacologic inhibition of CCR2 protected against the infiltration of neutrophils into the joints. This protection was not associated with an impairment of the neutrophil chemotactic ability or CXC chemokine production in the joints. Moreover, adoptive transfer of wild-type mouse neutrophils to CCR2-deficient mice restored neutrophil infiltration and the articular mechanical hyperalgesia associated with joint inflammation.
Conclusion. These findings suggest that CCR2 is directly involved in the detrimental infiltration of neutrophils into the joints in patients with RA, showing a new inflammatory role of CCR2 during RA flares or active disease.
Rheumatoid arthritis (RA) is an autoimmune arthropathy that is characterized by synovial hyperplasia, pain, and progressive movement disability (1, 2) . Neutrophils have long been implicated as key players in the initiation and progression of RA. In animal models of arthritis, it is well established that early signals of inflammation are correlated with the infiltration of neutrophils into articular spaces (3) (4) (5) . In RA patients with active disease, neutrophils are the most abundant leukocyte in synovial fluid. Furthermore, neutrophil depletion or pharmacologic blockade of neutrophil recruitment reduces the inflammation and bone damage in experimental arthritis (6) (7) (8) . However, the molecular mechanisms responsible for the infiltration of neutrophils into rheumatoid joints are not fully understood.
CCR2 (CC chemokine receptor type 2) is a receptor expressed in monocytes and lymphocytes, but not in neutrophils, in the physiologic state (9) (10) (11) (12) . Expression of neutrophil chemotactic receptors can change under conditions of acute inflammation or in response to specific inflammatory stimuli. During severe sepsis in mice, activated neutrophils lose their responsiveness to CXCR2 ligands by receptor internalization and express de novo CCR2, which is critical for infiltration of these cells into vital organs and for development of dysfunction in multiple organs (13) (14) (15) . Moreover, it was shown that infiltrated neutrophils from RA patients with chronic inflammatory lung disease highly express CC chemokine receptors, acquiring novel chemokine responsiveness at sites of inflammation (16) . Interestingly, several types of data support a role of CCR2 in the development of RA. CCR2 genetic polymorphisms modulate the risk of arthritis development in patients with psoriasis (17) . Moreover, CCL2, a CCR2 ligand, is found in high concentrations in the synovial fluid of RA patients (18) . However, the exact role of CCR2 in RA remains controversial (19) . CCR2 seems to be important for the functions of Treg cells and, thus, appears to have a role in arthritis progression (20) . However, CCR2 signaling could be proinflammatory, via its role in the recruitment of monocytes into the joints (21) (22) (23) . Indeed, it seems that CCR2 has a dual role in arthritis development; it is important for both the recruitment of proinflammatory cells during the acute phase and the function of suppressor cells during the chronic phase. In a mouse model of collagen-induced arthritis (CIA), CCR2 blockade at the beginning of the disease improved the clinical symptoms, whereas CCR2 blockade after the onset of the disease appeared to worsen the histologic signs of arthritis (19) . The aim of the present study was to determine whether the expression of the CCR2 chemokine receptor changes in neutrophils during the course of RA, and to assess the importance of this alteration in the infiltration of cells into the joints.
PATIENTS AND METHODS
Patients. For this study, 30 RA patients and 12 healthy subjects were recruited from the Division of Rheumatology at Hospital das Cl ınicas, Ribeirão Preto Medical School in Brazil (Tables 1 and 2 ). All subjects were Brazilians from the same geographically defined region. Subjects were diagnosed as having RA if they met at least 4 of the American College of Rheumatology 1987 revised classification criteria (24) . The diagnosis was determined by board-certified rheumatologists (RDRO and SCLA). Disease activity was evaluated using the Disease Activity Score in 28 joints (DAS28) (25) . The exclusion criteria adopted were the presence of another rheumatic disease or infectious disease, such as tuberculosis, Chagas' disease, hepatitis B or C virus, or human immunodeficiency virus infection. The concomitant diseases of systemic arterial hypertension, diabetes mellitus, dyslipidemia, and hypothyroidism were allowed for inclusion. All subjects provided informed consent to participate in the study, which was approved by the Ethics Committee of the University Hospital of Ribeirão Preto, University of São Paulo, Brazil (approval no. 2981/2009).
For analysis of messenger RNA (mRNA) expression, neutrophils were isolated from samples of peripheral blood collected from 24 patients with RA, all of whom had the disease for ,36 months (mean 6 SEM DAS28 4.51 6 0.37) (Table 1) , and from 9 healthy volunteers. For the chemotaxis assays, neutrophils were isolated from 6 patients with early RA who were receiving methotrexate monotherapy and had active disease (mean 6 SEM DAS28 5.31 6 0.48) and from 5 healthy volunteers (Table 2) . Mice. CCR2 2/2 mice were bred on the C57BL/6 background (26) and housed in the animal facility of the Ribeirão Preto Medical School. All mice received water and food ad libitum. The animal care and handling procedures were in accordance with the guidelines of the Animal Welfare Committee of Ribeirão Preto Medical School (approval no. 181/2008).
Antigen-induced arthritis (AIA) was induced in mice, using methylated bovine serum albumin (mBSA). Briefly, mice were sensitized subcutaneously (SC) with an emulsion containing mBSA (500 mg) and Freund's complete adjuvant (2 mg/ml of inactivated Mycobacterium tuberculosis) (both from Sigma-Aldrich) diluted 1:1 in phosphate buffered saline (PBS). Booster injections of mBSA dissolved in Freund's incomplete adjuvant (without M tuberculosis) were given 7 and 14 days after the first immunization. Sham-immunized mice received similar injections but without the antigen. Twenty-one days after the first immunization, arthritis was induced by an intraarticular (IA) injection (challenge) of mBSA or CCL2 in a final volume of 10 ml into the femorotibial joint. In some experiments, mice were treated SC with 2 mg/kg RS504393 (Tocris), a selective CCR2 antagonist (14) .
The extent of articular mechanical hyperalgesia in the mice after the mBSA challenge was evaluated with an electronic pressure meter, using a previously described method (3). This apparatus automatically records the mechanical threshold of articular flexion, and values are expressed in grams.
Neutrophil migration to the joints of mice was assessed 7 hours after mBSA challenge. The number of cells harvested from the articular cavities was counted using a previously described method (3) .
Purification of human and mouse neutrophils. Human and mouse neutrophils were purified from the peripheral blood using a Percoll gradient (Sigma-Aldrich), as previously described (14, 27) . Mature neutrophils were also purified from the bone marrow of mice, using a Percoll gradient as previously described (28) . The purity of neutrophil isolation (defined as presence of $97% neutrophils) was assessed by flow cytometry. Cell viability (defined as presence of $95% viable cells) was confirmed by trypan blue dye exclusion.
Chemotaxis assay. Chemotaxis assay was performed with human and mouse neutrophils using a 48-well chemotaxis chamber (Neuroprobe), as previously described (14) . Briefly, CXCL2 (R&D Systems), human CCL2, mouse CCL2, and mouse CCL7 (each from PeproTech) were diluted in Hanks' balanced salt solution medium and placed in the lower well of the chamber. Results are expressed as the number of neutrophils migrated per high-power field. In some assays, CCL2 was placed in both the upper and the lower wells of the chambers, thereby eliminating a chemical gradient and allowing the analysis of chemokinesis.
Flow cytometry. For flow cytometric analyses, human neutrophils were stained with fluorescein isothiocyanate (FITC)-conjugated anti-CD15 antibodies, and murine neutrophils were stained with FITC-conjugated anti-CCR2 (clone 475301; R&D Systems) and phycoerythrin-conjugated antiLy-6G/Gr-1 antibodies (clone 1A8; BD Biosciences). Flow cytometry was also performed in cells harvested from the mouse joints 7 hours after mBSA challenge. Analysis was performed on a FACSCanto cytometer, and the results were processed using FCS Express version 3 (De Novo Software).
Fluorescence microscopy. Neutrophils from the peripheral blood of mice were affixed to glass slides using cytocentrifuge, and then incubated with rabbit anti-mouse CCR2 and stained with Alexa Fluor 594-conjugated goat anti-rabbit IgG. In addition, the cells were incubated with DAPI (Invitrogen) to stain the cell nucleus. Representative fluorescence images were acquired using a Leica TCS SP5II confocal microscope. Images were captured using an Olympus BX-50 epifluorescence microscope to quantify the mean fluorescence intensity using ImageJ software.
Reverse transcription-polymerase chain reaction (RT-PCR) assays. Expression of CCR2 mRNA was measured in purified human and mouse neutrophils using RT-PCR, as previously described (14) . Real-time quantitative PCR (qPCR) was performed using primers specific for CCR2 or the housekeeping gene GAPDH (primer pair sequences are available upon request from the corresponding author). Reactions were conducted on an ABI Prism 7500 System using SYBR Green fluorescence (Applied Biosystems). Data was analyzed using the 2 2DDC t method (29) . Quantification of serum levels of anti-mBSA antibodies in mice. The titers of anti-mBSA antibodies in the mouse serum were measured by enzyme-linked immunosorbent assay (ELISA). Briefly, 96-well plates were coated with mBSA overnight at 48C. After blocking with 2% casein in PBS at room temperature for 1 hour, serial dilutions of serum were added and incubated overnight at 48C. For detection of antimBSA antibodies, biotin-conjugated rabbit anti-mouse IgG antibodies or anti-IgG2a-specific antibodies were incubated with mouse serum at room temperature for 2 hours. Finally, avidin-horseradish peroxidase was added for 30 minutes, the plates were washed, and orthophenylenediamine was added for 15 minutes. The reaction was stopped with 1M H 2 SO 4 and the optical density (OD) was read at 490 nm.
Cytokine measurements in mice. The CXCL2 and CCL2 cytokines were measured in homogenates of the knee joints of mice with AIA by ELISA, using paired antibodies (R&D Systems).
Adoptive transfer of neutrophils to mice with AIA. Bone marrow-purified neutrophils from immunized wild-type (WT) and CCR2 2/2 mice (each 5 3 10 6 cells; 98% purity) were intravenously (IV) injected into recipient immunized CCR2 2/2 mice. The recipient mice were challenged with mBSA, and 7 hours after challenge, articular hyperalgesia and neutrophil recruitment to the joints were evaluated.
Statistical analysis. Results are expressed as the mean 6 SEM and are representative of 2 separate experiments. Significance was determined using the Student's t-test or oneway analysis of variance with a Bonferroni post hoc test. P values less than 0.05 were considered statistically significant.
RESULTS
Expression of functional CCR2 in peripheral blood neutrophils from RA patients. We first evaluated whether neutrophils from RA patients express CCR2 AND NEUTROPHIL MIGRATION INTO RHEUMATOID JOINTSCCR2. For this purpose, neutrophils were isolated from the peripheral blood of RA patients (purity .97%) ( Figure 1A) , and expression of CCR2 mRNA was measured using qPCR. We found that peripheral blood neutrophils from RA patients showed higher CCR2 mRNA expression than that in the neutrophils from healthy control volunteers ( Figure 1B) .
To explore the functional significance of CCR2 up-regulation, we assayed neutrophil chemotaxis in response to CCL2 in vitro. We found that neutrophils from RA patients with active disease, but not those from healthy subjects, were responsive to CCL2. As shown in Figure 1C , neutrophils from RA patients exhibited significantly increased chemotaxis in response to CCL2 as compared to that in medium alone, with increases similar to those observed in response to CXCL8, a potent chemotactic factor for neutrophils (30) . Of note, the migration of blood neutrophils isolated from RA patients in response to CCL2 was inhibited when CCL2 was placed in both the upper and lower compartments of the chamber ( Figure 1D ). These results suggest that CCL2-induced neutrophil migration was chemotactic rather than chemokinetic.
Expression of functional CCR2 in neutrophils from mice with AIA. We next used the murine model of AIA to investigate the importance of CCR2 expression in neutrophils during RA. Using immunofluorescence staining and flow cytometry, we found that peripheral blood neutrophils from mice with AIA expressed CCR2; this expression was not found in neutrophils from sham-immunized or naive (untreated) mice (Figures 2A-C) . Moreover, synovial fluid neutrophils harvested from the articular cavities of mice with AIA after mBSA challenge also expressed CCR2 ( Figures 2B and C) . These results suggest that the active immunization process triggers the expression of CCR2 in neutrophils. Indeed, we observed an upregulation of Ccr2 mRNA in the blood neutrophils of mice 7 days after immunization ( Figure 2D ).
We then determined whether the expression of CCR2 in mouse neutrophils was functional. Similar to the cells from patients with RA, blood neutrophils from mice with AIA exhibited functional CCR2, since the cells were found to migrate in vitro toward CCR2 ligands (CCL2 and CCL7), whereas the neutrophils from sham-immunized mice did not migrate ( Figure  2E) . Notably, chemotaxis of the neutrophils from mice with AIA toward the CXCR1/CXCR2 ligand CXCL2 was normal, with migration levels similar to those of neutrophils from sham-immunized mice ( Figure 2E ).
As was observed in the studies of neutrophils from RA patients, when an equal concentration of CCL2 was added in the upper and lower wells in incubations with mouse peripheral blood neutrophils, no increase in neutrophil migration occurred ( Figure 2F ), indicating that migration was chemotactic rather than Figure 1 . Expression of functional CCR2 by neutrophils from rheumatoid arthritis (RA) patients. A, Flow cytometric analyses of CD151 neutrophil expression among total cells or among neutrophils isolated by Percoll gradient from the peripheral blood of a representative RA patient. B, CCR2 mRNA expression in blood neutrophils isolated from RA patients and healthy control subjects. Symbols represent individual subjects; horizontal lines show the mean. * 5 P , 0.05 by Mann-Whitney test. C, In vitro chemotaxis of human neutrophils in response to human CXCL8 or human CCL2 in peripheral blood samples from RA patients (n 5 6) and healthy controls (n 5 5). ** 5 P , 0.01 versus medium alone, by Student's t-test. D, In vitro chemotaxis of neutrophils toward CCL2 or CXCL8 in cells isolated from the peripheral blood of RA patients. In the assay, CCL2 was added in uniform concentrations in the lower well only or in both the upper and lower wells of the Boyden chamber. Results are expressed as the mean 6 SEM number of cells migrated per high-power field using samples from 3 RA patients and are representative of 2 independent experiments performed in triplicate. * 5 P , 0.01; # 5 P , 0.01 versus medium alone.
chemokinetic. Moreover, neutrophils from the bone marrow of mice with AIA were also responsive to CCL2 ( Figure 2G ). Importantly, we found that the chemotactic response toward CCL2 was specifically mediated by CCR2, because it was abolished in neutrophils from CCR2
2/2 mice with AIA ( Figure 2G ).
Required role of CCR2 in infiltration of neutrophils into the joints of arthritic mice. CCL2 has been observed to be up-regulated in the synovial fluid of patients with RA (18) . Similarly, our findings indicated an up-regulation of CCL2 in the joints of mice with AIA after mBSA challenge ( Figure 3A) . We therefore Figure 3B ). This migration was not observed in the sham-immunized mice. Interestingly, the pharmacologic blockade of CCR2 with RS504393 ( Figure 3C ) and the knockout of CCR2 ( Figure 3D ) each reduced the neutrophil migration to the articular cavities of mice after the joint challenge with mBSA or CCL2. Similarly, ovalbumin-immunized mice also showed CCR2-dependent neutrophil migration (data not shown), suggesting that the CCR2 response is not antigen specific. Moreover, it is important to note that there were no significant differences between WT and CCR2 2/2 mice (n 5 3 mice/group) in the absolute number of total peripheral blood leukocytes (mean 6 SEM 8.83 6 0.25 versus 7.58 6 0.4 cells 3 10 6 /ml) or peripheral blood neutrophils (1.674 6 0.067 versus 1.306 6 0.139 cells 3 10 6 /ml). The hyperalgesia that develops in the joints during arthritis is neutrophil dependent (3). Accordingly, reduced articular mechanical hyperalgesia was observed in CCR2 2/2 mice compared with WT mice after mBSA challenge ( Figure 3E) . CCR2 knockout or pharmacologic receptor blockade did not reduce the production of the chemokines CXCL2 and CCL2 in the joints (Figures 3F and G) . Indeed, CCR2
2/2 mice showed increased levels of CXCL2 when compared with WT mice (Figure 3F ), which could be a compensatory mechanism. Furthermore, the serum titers of total IgG and IgG2a anti-mBSA antibodies were not significantly different between WT and CCR2 2/2 mice, suggesting that the reduced acute inflammation in CCR2 2/2 mice was not related to impaired immunization ( Figure 3H ).
Finally, we investigated whether the expression of CCR2 in neutrophils could be directly related to the migration of cells from the blood into the joints during AIA. For this purpose, blood neutrophils were isolated from WT or CCR2 2/2 mice with AIA and were adoptively transferred IV to CCR2 2/2 mice with AIA; these mice were then challenged with an IA injection of mBSA. We found significantly more neutrophils in the articular cavities of the mice that received WT mouse neutrophils compared with those that received CCR2 2/2 mouse neutrophils ( Figure 4A ). Moreover, CCR2
2/2 mice that received WT mouse neutrophils showed increased articular mechanical hyperalgesia compared with mice that received CCR2 2/2 mouse neutrophils ( Figure 4B ). Taken together, these data indicate that CCR2 plays an important direct role in the migration of neutrophils into the joints during arthritis.
DISCUSSION
In the present study, we have demonstrated that the expression of chemotactic receptors in neutrophils changes during the development of an acquired immune response, and that this alteration is important for the further migration of these cells into the inflamed tissue. Evidence from previous studies indicates that under certain acute inflammatory conditions, such as sepsis and adjuvant-induced vasculitis, neutrophils express de novo, functional CCR2 (14, 15, 31) . Moreover, Hartl et al (16) observed that, after infiltration into the inflamed synovium, neutrophils from RA patients acquire expression of CC chemokine receptors and functional responsiveness. Those authors suggested that this new chemokine receptor repertoire enables neutrophils to adapt to the environment of chronic inflammation, making them responsive to the surrounding chemokines in the inflamed tissue.
The results of the present study extend the previous findings by showing that neutrophils from RA patients and from mice with AIA are already expressing functional CCR2 in the peripheral blood. Moreover, we also found that bone marrow neutrophils from mice with AIA are responsive to CCR2 ligands, suggesting that these cells can already leave bone marrow with an altered chemotactic receptor repertoire during arthritis. These results suggest that during the robust activation of adaptive immunity, functional changes occur not only in adaptive immune cells but also in innate effector cells, such as neutrophils.
Our findings also show a functional importance of CCR2 expression in neutrophils with regard to their infiltration into the joint and the further development of signs of early arthritis. We found that the knockout or pharmacologic inhibition of CCR2 in mice with AIA markedly reduced the migration of neutrophils into the joints after antigen challenge. Accordingly, blockade of CCR2 also reduced articular mechanical hyperalgesia, a clinical feature of early arthritis closely related to neutrophil infiltration (3) . Notably, the adoptive transfer of neutrophils from WT mice with AIA to CCR2 2/2 mice restored neutrophil migration into the joints, and consequently, inflammatory hyperalgesia was increased. These findings do not rule out the possibility of a role of CCR21 monocytes in the recruitment of neutrophils (32, 33) , but they do indicate that CCR2 expressed in neutrophils is also important for the direct recruitment of this cell into the joints during ongoing RA.
It is worth mentioning that the knockout or pharmacologic inhibition of CCR2 did not completely abolish the neutrophil recruitment. This finding could be explained by the fact that neutrophils from immunized 2/2 mice with antigen-induced arthritis (AIA) were transferred to CCR2 2/2 mice 1 hour before intraarticular (IA) challenge with methylated bovine serum albumin (mBSA). A, Neutrophil migration to the articular cavities of mice with AIA was examined 7 hours after intraarticular challenge with mBSA. B, Articular mechanical hyperalgesia was examined in mice after adoptive transfer of neutrophils and intraarticular antigen challenge. Results are the mean 6 SEM of 5 mice per group. * 5 P , 0.05 by analysis of variance followed by Bonferroni post hoc test.
CCR2 AND NEUTROPHIL MIGRATION INTO RHEUMATOID JOINTSmice are still responsive to CXCL2, a classic chemokine involved in the recruitment of neutrophils to inflamed joints (34) . However, this ability of neutrophils to respond to CXCL2 did not allow the restoration of normal neutrophil infiltration in the absence of CCR2 signaling. Therefore, these 2 chemokines are probably acting synergistically to mediate neutrophil infiltration into the joints during arthritis.
Our findings seem to differ from the results reported in the literature regarding the effect of CCR2 in mice with CIA and the spontaneous arthritis that develops in mice deficient in interleukin-1 receptor antagonist, in which CCR2 deficiency aggravates the disease (35, 36) . However, the exacerbation of CIA by the blockade of CCR2 is associated with a reduction of Treg cell function during the chronic phase of the disease (19) . In humans, CCR2 inhibitors failed to show beneficial effects in patients with established RA during phase II trials (37, 38) . One hypothesis is that the lack of efficacy could be explained by the impairment of immunosuppressive mechanisms related to the role of CCR2 on Treg cells. Our results do not negate the role of CCR2 in immune regulation over the progression phase of arthritis, but they do add a new role of CCR2 in the development of the acute phase of early arthritis. Indeed, the rationale for predicting therapeutic benefits of a CCR2 inhibitor during early RA can also be supported by previous data showing that blockade of CCR2 during initiation of CIA ameliorates clinical disease as measured by disease activity scores (19) . Taken together, our findings show the importance of CCR2 for recruiting neutrophils into the joints during the acute phase of early RA. These findings thus reinforce the possibility that CCR2 inhibitors could be tested as a potential adjuvant therapy in patients during early RA and during episodes of disease flare.
